Search

News Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients

Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody against IL-17A and IL-17F, bimekizumab, in patients with plaque psoriasis using a prefilled syringe or autoinjector.

Source: Psoriasis 3. 6. 2022

News Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol

A newly published study by authors from Singapore focused on the ability of the SEP protocol –⁠ short-term low-dose enoxaparin administration based on body weight –⁠ to maintain the patency of an arteriovenous (A-V) shunt after recurrent thrombosis.

Source: Thromboprophylaxis 3. 1. 2024

News Study AMPLIFY Confirmed Safety and Efficacy of Fixed Combination Aclidinium/Formoterol in COPD Therapy

The randomized double-blind phase III AMPLIFY study compared the efficacy of a fixed combination of formoterol/aclidinium with monotherapy of the individual components or with tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

Source: Treatment of Asthma and COPD 15. 7. 2020

News Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate

The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA) inadequately controlled by methotrexate demonstrated the benefit of adding baricitinib or adalimumab compared to placebo in terms of reducing the number of swollen joints. However, baricitinib showed greater pain relief starting from week 1 compared to placebo and from week 2 compared to adalimumab. Thus, the recently published results of an analysis using the data from this study aimed to compare the proportion of patients who achieved certain pain relief thresholds, the time required for pain relief, and the relationship between the presence of inflammation and pain.

Source: Biological Treatment 17. 2. 2020

News Does Intense Monitoring After Colorectal Cancer Resection Bring Benefits?

Is it necessary to intensely monitor patients with colorectal cancer after curative resection? Not always, as shown by the results of the PRODIGE 13 study presented at the virtual ESMO 2020 conference.

Source: Colorectal Cancer 25. 5. 2021

News Spectrum of Mechanisms of Action of Fenfluramine in the Treatment of Rare Epilepsies

Fenfluramine (FFA) is an anticonvulsant used in the treatment of rare epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. In addition to effectively reducing seizure frequency, it also mitigates non-seizure comorbidities in patients with these conditions. Last year, Belgian authors published a detailed review of all its described mechanisms of action. They also explain how these mechanisms might contribute to the clinical benefits of FFA beyond seizure suppression, such as reducing the risk of sudden unexpected death in epilepsy (SUDEP) or improving executive functions.

Source: Rare Diseases in Neurology 21. 6. 2024

News Vaccination and ALEmtuzumab: ALE when?

When, why and against what should patients with multiple sclerosis treated with alemtuzumab be vaccinated? And is vaccination effective in this population?

Source: Multiple Sclerosis 5. 6. 2023

News Pharmacokinetics and Safety Profile of Bilastine in Patients Aged 6–11 Years –⁠ Findings from Post-hoc Analysis of Studies

The second-generation antihistamine bilastine is approved in Europe for the treatment of allergic rhinoconjunctivitis and urticaria in children over 6 years old. Post-hoc analyses of two clinical studies focused on its safety profile and pharmacokinetics in the pediatric population.

Source: Allergic Reactions 4. 3. 2020

News How did alemtuzumab fare in real clinical practice?

A study published by authors from the University of Massachusetts in January this year in the journal Multiple Sclerosis and Related Disorders focused on the effectiveness and safety of alemtuzumab. How did it fare in real clinical practice?

Source: Multiple Sclerosis 11. 6. 2021

News Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year −⁠ A US Experience

The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.

Source: Hemophilia 27. 11. 2023

News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease

Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.

Source: Parkinson's Disease 10. 3. 2023

News Untreated Bleeding in Hemophilia A –⁠ An Underestimated Problem? To What Extent?

How common is bleeding in hemophilia A that ultimately goes untreated? This was the focus of a recent study, the results of which were published in the journal Research and Practice in Thrombosis and Hemostasis.

Source: Hemophilia 27. 11. 2023

News Can the Treatment of Hypertension Prevent Recurrence of Atrial Fibrillation?

Atrial fibrillation (Afib) is the most common serious heart rhythm disorder and is responsible for a significant portion of deaths in the population. Hypertension is the most common and potentially modifiable risk factor for Afib. A newly published meta-analysis compares the effect of angiotensin receptor antagonism and calcium channel blockade on Afib recurrence in patients with hypertension and Afib.

Source: Sartans in the Treatment of Hypertension 3. 12. 2021

News Meta-analysis of the efficacy and safety of dupilumab in the treatment of atopic dermatitis in children and adults

Moderate to severe atopic dermatitis (AD) is accompanied by strong inflammatory processes that can occur anywhere on the skin, intense itching, and pain. The biologic dupilumab is a promising molecule for the treatment of severe forms of this condition –⁠ results from a recently published meta-analysis indicate that this therapy is not only effective but also well-tolerated by patients.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 13. 6. 2023

News Dupilumab in the Treatment of Adolescent Patients with Severe and Refractory Atopic Dermatitis

An open multicenter study evaluating dupilumab in the treatment of moderate to severe atopic dermatitis in adolescents confirmed its long-term efficacy and safety in this age group. In addition to its results, we also summarize information on dosing and reimbursement conditions in the Czech Republic for the age group 12-18 years.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 12. 2020